Hemofiltration as an Alternative for IL-6 Inhibitors in COVID-19 Cytokines Storm Associated with Underlaying Bacterial Infections: A Review Article.

Q3 Pharmacology, Toxicology and Pharmaceutics

Infectious disorders drug targets Pub Date : 2023-01-01 DOI:10.2174/1871526523666230502143507

Samy Zaky, Mohamed El Badry, Hoda A Makhlouf, Sherief M Abd-Elsalam, Tarik S Sarhan, Noha H Eltaweel, Heba Aly, Akram Abdelbary, Ahmed Said, Mohammed Hamdy Farouk, Amin Abdelbaki, Hanaa Fathelbab, Reham Hammad, Fathiya El-Raey

引用次数: 0

Abstract

SARS-CoV-2 causes mostly mild cases. However, a considerable number of patients develop fatal acute respiratory distress syndrome due to the cytokine storm and imbalanced immune response. Several therapies depending on immunomodulation have been used, including glucocorticoids and IL-6 blockers. However, their efficacy is not perfect with all patients and patients with concomitant bacterial infections and sepsis. Accordingly, studies on different immunomodulators, including extracorporeal techniques, are crucial to save this category of patients. In this review, we overviewed the different immunomodulation techniques shortly, with a brief review of extracorporeal methods.

查看原文本刊更多论文

血液滤过作为IL-6抑制剂在COVID-19细胞因子风暴相关的潜在细菌感染中的替代方案:综述文章

SARS-CoV-2引起的大多是轻微病例。然而，由于细胞因子风暴和不平衡的免疫反应，相当多的患者发生致命的急性呼吸窘迫综合征。几种依赖免疫调节的治疗方法已经被使用，包括糖皮质激素和IL-6阻滞剂。然而，对于所有患者以及合并细菌感染和败血症的患者，其疗效并不完美。因此，研究不同的免疫调节剂，包括体外技术，对于拯救这类患者至关重要。在这篇综述中，我们简要概述了不同的免疫调节技术，并简要回顾了体外方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious disorders drug targets Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

3.10

自引率

0.00%

发文量

123

期刊介绍： Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continues to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.